Market Place
Sourcing Support
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote
31 Aug 2023 //
GLOBENEWSWIRE
Surface Oncology Reports Financial Results for Second Quarter 2023
02 Aug 2023 //
GLOBENEWSWIRE
Surface warns bankruptcy possible if shareholders reject merger
02 Aug 2023 //
FIERCE BIOTECH
Surface Oncology Reports Financial Results and Corporate Highlights for 1Q 2023
04 May 2023 //
GLOBENEWSWIRE
Surface Oncology Presents New Preclinical Data on SRF114,
18 Apr 2023 //
GLOBENEWSWIRE
Surface Oncology to Present New Preclinical SRF114 Data at AACR
16 Mar 2023 //
GLOBENEWSWIRE
Surface Oncology Reports Financial Results for Fourth Quarter and Full Year 2022
09 Mar 2023 //
GLOBENEWSWIRE
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
28 Feb 2023 //
GLOBENEWSWIRE
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
02 Feb 2023 //
GLOBENEWSWIRE
Surface Oncology Announces First Patient Dosed in a Ph 1/2 Study SRF114
05 Jan 2023 //
GLOBENEWSWIRE
Surface to Present Non-clinical Data for SRF388 and SRF114 at the 2022 Meeting
07 Nov 2022 //
GLOBENEWSWIRE
Surface Oncology to lay off 20% of staff in restructuring
03 Nov 2022 //
BIOPHARMADIVE
Surface Oncology Announces Promising SRF388 Monotherapy Data in NSCLC
02 Nov 2022 //
GLOBENEWSWIRE
VIB & Surface Oncology Announce Publication Revealing IL-27 Structure for SRF388
19 Oct 2022 //
GLOBENEWSWIRE
Surface Oncology to Present Preclinical Data the IL-27 Gene Expression
14 Sep 2022 //
GLOBENEWSWIRE
Surface to Participate in the Gilmartin Group Emerging Growth Company Showcase
24 Aug 2022 //
GLOBENEWSWIRE
Surface Oncology Reports Financial Results for Second Quarter 2022
03 Aug 2022 //
GLOBENEWSWIRE
Surface Oncology to Participate in 2022 Wedbush PacGrow Healthcare Conference
01 Aug 2022 //
GLOBENEWSWIRE
Surface Oncology Appoints Carsten Brunn to Board of Directors
29 Jun 2022 //
GLOBENEWSWIRE
Surface Oncology Announces Publication of New Study of IL-27 Pathway
20 Jun 2022 //
GLOBENEWSWIRE
Surface Oncology to Participate in Upcoming Investor Conferences
01 Jun 2022 //
GLOBENEWSWIRE
Surface Oncology to Present New SRF388 Clinical Data at 2022 ASCO
26 May 2022 //
GLOBENEWSWIRE
Surface Oncology to Participate in Upcoming Investor Conferences
17 May 2022 //
GLOBENEWSWIRE
Surface Oncology Reports Financial Results for First Quarter 2022
09 May 2022 //
GLOBENEWSWIRE
Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06 May 2022 //
GLOBENEWSWIRE
Surface Oncology to Present Clinical Update on SRF388 at ASCO
27 Apr 2022 //
GLOBENEWSWIRE
Surface Oncology Initiates PII Studies of SRF388 in HC and NSCLC
14 Apr 2022 //
GLOBENEWSWIRE
Surface Oncology Presents New SRF388 Data at the AACR
08 Apr 2022 //
GLOBENEWSWIRE
Surface Oncology Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
01 Apr 2022 //
GLOBENEWSWIRE
Surface Oncology Achieves $30M Milestone with 1st Patient Dosed in GSK Phase 1
31 Mar 2022 //
GLOBENEWSWIRE
Surface Oncology Appoints Theresa Boni as General Counsel
15 Mar 2022 //
GLOBENEWSWIRE
Surface Oncology Reports Financial Results and Corporate Highlights for 2021
02 Mar 2022 //
GLOBENEWSWIRE
Surface Oncology to Participate in Novel Immuno-Oncology Panel
28 Feb 2022 //
GLOBENEWSWIRE
Surface Oncology to Participate in Citi`s 2022 Virtual Immuno-Oncology Summit
10 Feb 2022 //
GLOBENEWSWIRE
Surface Oncology to Present New Clinical Data from Ongoing SRF617
02 Dec 2021 //
GLOBENEWSWIRE
Preclinical Data Supporting Potential of Surface Oncology’s SRF617 and SRF388
09 Nov 2021 //
GLOBENEWSWIRE
Surface Oncology Announces New Randomized Ph2 Clinical Study Evaluating SRF388
04 Oct 2021 //
GLOBENEWSWIRE
Surface Oncology Announces New Randomized Ph2 Clinical Study Evaluating SRF388
04 Oct 2021 //
GLOBENEWSWIRE
Surface Oncology Reports Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Surface Oncology Appoints Denice Torres to Board of Directors
08 Jul 2021 //
GLOBENEWSWIRE
Surface Oncology to Present Clinical Updates for SRF388 and SRF617
28 Apr 2021 //
GLOBENEWSWIRE
Surface Oncology Presents Promising Preclinical Data for Lead Product
09 Apr 2021 //
GLOBENEWSWIRE
Surface Oncology’s SRF617 Receives Orphan Drug Designation from FDA
30 Mar 2021 //
GLOBENEWSWIRE
Surface Oncology to Present Preclinical Data for Lead Product Programs
10 Mar 2021 //
GLOBENEWSWIRE
Merck inks Keytruda deal with Surface Oncology; Rocket Pharma gets expedited
09 Mar 2021 //
ENDPTS
Surface Ophthalmics Announces First Patient Dosed in Ph II Trial for SURF-200
04 Feb 2021 //
PRNNEWSWIRE
Surface Ophthalmics Announces First Patient Dosed Head-to-Head Phase II
27 Jan 2021 //
PRNEWSWIRE
Surface Ophthalmics Previews Important Clinical Progress in 2021
07 Jan 2021 //
PRNEWSWIRE
GSK puts up to $815M on the table for Surface Oncology`s antibody
18 Dec 2020 //
FIERCE BIOTECH
Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination
13 Nov 2020 //
GLOBENEWSWIRE
Surface Oncology Announces FDA Fast Track Granted by USFDA for SRF388
11 Nov 2020 //
GLOBENEWSWIRE
Surface Oncology to Present SRF388 and SRF114 Preclinical Data at the Upcoming
09 Nov 2020 //
GLOBENEWSWIRE
Silence Therapeutics wants to list on Nasdaq while pursuing new deals
20 May 2020 //
ENDPTS
Surface Oncology to Present at the American Society of Clinical Oncology
14 May 2020 //
GLOBENEWSWIRE
Surface Oncology Announces First Patient Dosed in Trial of Antibody SRF388
23 Apr 2020 //
GLOBENEWSWIRE
